Biotrial’s Post

A new contribution from Biotrial's preclinical department to the development of new treatments for psychiatric disorders

There were no surprises when results from the PHOENIX study of Amylyx Pharmaceuticals' ill-fated Relyvrio were presented at the American Academy of Neurology (AAN) annual meeting this week, but details from the confirmatory trial reveal the extent of how poorly the #amyotrophiclateralsclerosis (ALS) drug performed. https://lnkd.in/dPA3mpvF #AAN #ALS #Amylyx #biotechnology #clinicalresearch #clinicaltrials #drugdevelopment #FDA #pharmaceuticals #regulatoryaffairs

$MIRA Exciting News from MIRA Pharmaceuticals! We are thrilled to announce groundbreaking preclinical results for our novel oral ketamine analog, Ketamir-2. These findings mark a significant milestone in our journey to revolutionize the treatment of neurological and neuropsychiatric disorders. Key Highlights: ✅ Optimized Brain Delivery: Ketamir-2 has shown enhanced brain penetration by not interacting with P-glycoprotein (P-gp), a common barrier in drug delivery. ✅ Increased Bioavailability: Preclinical studies predict an impressive 80% oral bioavailability, compared to less than 30% for traditional ketamine. ✅ Improved Safety Profile: Ketamir-2 potentially avoids common side effects and dependency risks associated with traditional ketamine, showing no interaction with the mu-opioid receptor. ✅ Convenient Oral Administration: Unlike traditional ketamine, which requires IV administration, Ketamir-2’s oral formulation promises greater patient convenience and compliance. ✅ Promising Therapeutic Potential: Ketamir-2 demonstrates significant antidepressive and anxiolytic effects, and it shows potential for lower dosing with higher efficacy. We are also exploring the potential of Ketamir-2 for treating chemotherapy-induced depression, cancer-related neuropathic pain, and orphan drug indications like multiple sclerosis and Huntington’s disease-induced depression. Just so you know, the results mentioned are from preclinical studies and are still under investigation. We are not making any claims regarding its safety or efficacy at this time. Ketamir-2 & Mira-55 have not been approved by the FDA, and further studies are necessary to determine their potential for human use. #Mira #Ketamir-2 #Depression #Orphandrug #Chemo #Pain #PTSD #Drugdiscovery #Ketamin #FDA #TRD #Suicide https://lnkd.in/enUXuFxW

MIRA Pharmaceuticals is excited to update you on our latest research developments. Currently, MIRA Pharmaceuticals is advancing the preclinical study of Ketamir, a Novel unscheduled oral #ketamine analog, exploring its potential applications in treating Treatment-Resistant Depression (TRD), Major Depression Disorder with Suicidal Ideation (MMDSI), Post-Traumatic Stress Disorder (PTSD), and neuropathic pain. Please stay informed about our rigorous scientific journey by checking out the updated research provided by Zacks Investment Research, which I've attached here. #ketamir #depression #ptsd #cancerpain #neurophathicpain #TRD #ketamine #ketaminetherapy https://lnkd.in/edCheW5J

🌍 Exciting Collaboration in Pharma! 🤝 Autifony Therapeutics and Jazz Pharmaceuticals join forces in the pursuit of groundbreaking treatments for rare #CNS disorders and serious brain diseases. 🧠💊 Autifony Therapeutics, a #UK-based #biotech company, known for its focus on rare CNS disorders, teams up with Ireland's Jazz Pharmaceuticals for an exclusive global licensing agreement. This collaboration has the potential to bring about innovative solutions and advancements in the field. 🚀 The partnership could lead to up to $770.5 million in earnings for #Autifony, marking a significant milestone in their mission to address unmet medical needs. 🌐 Connect with me for more insights into this exciting development and stay updated on the latest in the pharmaceutical industry! 👥🔍 #AutifonyTherapeutics #JazzPharmaceuticals #PharmaCollaboration #CNSDisorders #InnovationInPharma #HealthcareAdvancements #GlobalLicensing #Pharmaceuticals #RareDiseases #Neurology

$MIRA Exciting News from MIRA Pharmaceuticals! We are thrilled to announce groundbreaking preclinical results for our novel oral ketamine analog, Ketamir-2. These findings mark a significant milestone in our journey to revolutionize the treatment of neurological and neuropsychiatric disorders. Key Highlights: ✅ Optimized Brain Delivery: Ketamir-2 has shown enhanced brain penetration by not interacting with P-glycoprotein (P-gp), a common barrier in drug delivery. ✅ Increased Bioavailability: Preclinical studies predict an impressive 80% oral bioavailability, compared to less than 30% for traditional ketamine. ✅ Improved Safety Profile: Ketamir-2 potentially avoids common side effects and dependency risks associated with traditional ketamine, showing no interaction with the mu-opioid receptor. ✅ Convenient Oral Administration: Unlike traditional ketamine, which requires IV administration, Ketamir-2’s oral formulation promises greater patient convenience and compliance. ✅ Promising Therapeutic Potential: Ketamir-2 demonstrates significant antidepressive and anxiolytic effects, and it shows potential for lower dosing with higher efficacy. We are also exploring the potential of Ketamir-2 for treating chemotherapy-induced depression, cancer-related neuropathic pain, and orphan drug indications like multiple sclerosis and Huntington’s disease-induced depression. Please note: The results mentioned are from preclinical studies, and Ketamir-2 & Mira-55 are still under investigation. We are not making any claims regarding its safety or efficacy at this time. Ketamir-2 has not been approved by the FDA, and further studies are necessary to determine its potential for human use. #Mira #Ketamir-2 #Depression #Orphandrug #Pain #Drugdiscovery #Ketamin #FDA #TRD #Suicide #PTSD https://lnkd.in/enUXuFxW

NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments #brain #Parkinson #Synuclein #LewyBodyDementia #dementia #research #science Published: Jun 27, 2024 ZURICH, SWITZERLAND / ACCESSWIRE / June 27, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced preclinical results from multiple in vitro studies targeting alpha-synuclein (α-synuclein), specifically the A53T mutation, that demonstrate the compounds' potential to advance the treatment of Parkinson's Disease (PD). The compounds may be used by NLS pursuant to its existing and previously announced license agreement with Aexon Labs, Inc. (Aexon Labs or AEX). https://lnkd.in/esarhBZb

#ASH23 is two weeks away. Interested in learning about the only patient-centric outcomes research platform that measures heterogeneous patient experiences, as well as real-time treatment utilization and acute events/exacerbations? Check out our accepted abstracts, or request a 1-1 meeting with Folia, via the link: #flares #oncology #hematology #sicklecelldisease

The field of drug development is constantly evolving. From new #cancer treatments to innovative therapies for liver and #neurological conditions, new advancements in #pharmaceuticals represent significant strides in #medical science. Discover more about the groundbreaking drugs from Astellas Pharma, Madrigal Pharmaceuticals, and Karuna Therapeutics (BMS) that are set to transform patient care in the coming years. Check out our complete report on the Healthark Insights website - https://lnkd.in/ehCi-ZQG #Pharmaceuticals #DrugApproval #MedicalInnovation #ClinicalResearch #NewTherapies #LifeSciences #FutureOfMedicine #PatientCare #FDAApproval

Epilepsy, with its unpredictable seizures, not only affects the individual but also burdens families and communities with fear, stigma, and uncertainty. Despite medical advancements, treatment remains a labyrinth of trial and error, with medications often carrying side effects or proving ineffective for some. The quest for effective therapies persists, fueled by the collective efforts of pharmaceutical companies dedicated to innovation and research. Yet, amidst the hurdles, there is hope. Companies such as UCB, Stoke Therapeutics, Xenon Pharmaceuticals Inc., Epygenix Therapeutics, Inc., Bright Minds Biosciences, Neurona Therapeutics, PTC Therapeutics, Inc., Addex Pharmaceuticals Ltd, Équilibre BioPharmaceuticals Corp., Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice Pharma, Virpax Pharmaceuticals Inc. (Nasdaq:VRPX), Neuroene Therapeutics and others are rallying behind the cause, investing in groundbreaking research and development to discover novel treatments and improve existing therapies. From developing new antiepileptic drugs with improved efficacy and tolerability to exploring innovative seizure management devices and precision medicine approaches, the pharmaceutical industry is at the forefront of driving progress in epilepsy care. In the realm of epilepsy treatment and pharmaceutical development, DelveInsight Business Research LLP at its end plays a role. It serves as an invaluable partner to pharmaceutical giants, providing key insights and strategic guidance that shape the direction of research, development, and marketing efforts. Together, we can transform the landscape of epilepsy treatment, ensuring that no one faces this journey alone and that every individual can live life to the fullest, free from the shackles of seizures. #epilepsyawareness #endepilepsystigma #seizureawareness #epilepsywarrior #supportepilepsy #epilepsyresearch #epilepsycommunity #livingwithepilepsy #epilepsyeducation #epilepsyfighters #epilepsyadvocacy #epilepsyresearch #epilepsyawarenessmonth #epilepsycare #epilepsystrong